Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamics of AT-007 in Pediatric Patients With Classic Galactosemia (CG)

NCT04902781 is registered in ClinicalTrials.gov with Applied Therapeutics, Inc. as lead sponsor.

NCT NCT04902781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04902781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamics of AT-007 in Pediatric Patients With Classic Galactosemia (CG)
Lead sponsor
Applied Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
March 20, 2021
Completion date
May 21, 2025
Enrollment
47 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

classic galactosemia